Sponsor

Targacept Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Targacept Inc. appears in 14 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials14
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

14 shown
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With SchizophreniaNCT01488929 · lead sponsor · 2011-12-01
COMPLETED
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)NCT01466088 · lead sponsor · 2011-10-01
COMPLETED
TC-6987 for the Treatment of Mild to Moderate AsthmaNCT01296087 · lead sponsor · 2011-02-01
COMPLETED
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes MellitusNCT01293669 · lead sponsor · 2011-01-01
COMPLETED
Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's DiseaseNCT01254448 · lead sponsor · 2010-09-01
COMPLETED
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in SchizophreniaNCT01003379 · lead sponsor · 2009-10-01
COMPLETED
TC-5214 as Augmentation Therapy in Patients With Refractory HypertensionNCT00899977 · lead sponsor · 2009-05-01
TERMINATED
TC-5214 as add-on the Treatment of Major Depressive DisorderNCT00692445 · lead sponsor · 2008-06-01
COMPLETED
Flexible Dose Titration Add-on Study to Treat Major Depressive DisorderNCT00593879 · lead sponsor · 2005-02-01
COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01180400 · collaborator · 2010-09-01
COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.NCT01197508 · collaborator · 2010-09-01
COMPLETED
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01152554 · collaborator · 2010-06-01
COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)NCT01157078 · collaborator · 2010-06-01
COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01153347 · collaborator · 2010-06-01
COMPLETED

Sponsor roles

lead sponsor9
collaborator5
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.